Schwab, Roland and Kabbasch, Christoph and Goertz, Lukas and Kaschner, Marius and Weiss, Daniel and Loehr, Christian and Wensing, Hauke and Bester, Maxim and Simgen, Andreas and Kemmling, Andre and Wendl, Christina and Fuchs, Erelle and Thormann, Maximilian and Behme, Daniel and Nordmeyer, Hannes (2025) The DERIVO 2 Heal Embolization Device in the Treatment of Ruptured and Unruptured Intracranial Aneurysms: a Retrospective Multicenter Study. CLINICAL NEURORADIOLOGY, 35 (1). pp. 25-34. ISSN 1869-1439, 1869-1447
Full text not available from this repository. (Request a copy)Abstract
BackroundThe use of flow diverting stents in the treatment of intracranial aneurysms is associated with a risk of neurological morbidity due to their thrombogenicity. To reduce this risk different surface modifications have been developed. The Derivo 2 Embolization Device (Acandis, Pforzheim, Germany) has proven to be a safe and effective flow diverter. To overcome the risk of thrombo-embolism, the device was modified by adding an anti-thrombogenic fibrin-heparin coating. We aimed to assess the safety and effectiveness of the Derivo 2 heal Embolization Device. Methods Retrospective multicenter data from nine German neurovascular centers between February 2022 until December 2023 were used. Patients treated with the Derivo 2 heal Embolization Device for unruptured or ruptured intracranial aneurysms were included. Peri- and postprocedural adverse events, clinical outcomes, and angiographic follow-up results were evaluated. Results 84 patients (73.8% female; mean age 58.7 years) with 89 aneurysms (mean size 9.8 mm) were included. 87.6% were located in the anterior circulation. Most of them were sidewall aneurysms (88.8%). 96 flow diverters were used. 99.0% were successfully implanted. An in-stent balloon angioplasty was performed in 6.0% of the cases. An additional coiling was performed in 28.6%. Technical difficulties were present in 12.0% of the cases. Thrombotic events occurred in 4.8% with no neurological sequelae. Mortality and morbidity were 0 and 1.2% respectively. Adequate aneurysm occlusion was achieved in 80.7% with a mean follow-up time of 6.6 months. ConclusionThe Derivo 2 heal Embolization Device showed a satisfying aneurysm occlusion and safety with a low rate of neurological morbidity.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | FLOW-DIVERTOR DEVICES; RESTENOSIS; SAH; hemorrhage; flow diverter; endovascular treatment; cerebral aneurysm |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Röntgendiagnostik |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 31 Mar 2026 08:45 |
| Last Modified: | 31 Mar 2026 08:45 |
| URI: | https://pred.uni-regensburg.de/id/eprint/65346 |
Actions (login required)
 |
View Item |
